FDA Denies Stoke Therapeutics’ Request for Fast-Track Drug Approval

Stoke Therapeutics announced that it has not reached an agreement with the Food and Drug Administration (FDA) regarding an expedited submission for its treatment aimed at severe epilepsy. This decision, shared on Sunday, affects the company’s hopes to fast-track the approval of zorevunersen, a potential therapy for Dravet syndrome.

Following a meeting in December 2023, the FDA did not outright deny Stoke’s request to submit the drug for approval this year. Instead, the agency requested additional information before making a final decision. This means that Stoke must wait for the completion of an ongoing Phase 3 study, which is expected to conclude in the middle of 2027, unless further discussions yield a different outcome.

Stoke’s Chief Executive Officer, Ian Smith, conveyed this information during an interview, indicating that the company is still optimistic about finding a regulatory pathway for zorevunersen. “We are working closely with the FDA and are committed to providing the necessary data to facilitate this process,” Smith stated.

The potential delay in the approval of zorevunersen is significant as it represents a crucial treatment option for patients suffering from Dravet syndrome, a severe form of epilepsy that often begins in infancy. This condition can lead to frequent and severe seizures, severely impacting the quality of life for both patients and their families.

Stoke Therapeutics is now expected to make a decision regarding its regulatory strategy for zorevunersen by the middle of this year. The company remains engaged in discussions with the FDA to explore viable options that could expedite the review process.

As the situation develops, Stoke aims to keep stakeholders informed and will provide updates as new information becomes available. The ongoing dialogue with the FDA highlights the complexities involved in drug approval processes, particularly for treatments aimed at rare and severe medical conditions.